Emerging Opportunities and Challenges of Biosimilars in Oncology Practice.
Publication
, Journal Article
Lyman, GH
Published in: J Oncol Pract
September 2017
Duke Scholars
Published In
J Oncol Pract
DOI
EISSN
1935-469X
Publication Date
September 2017
Volume
13
Issue
9_suppl
Start / End Page
7s / 9s
Location
United States
Related Subject Headings
- United States
- Oncology & Carcinogenesis
- Neoplasms
- Medical Oncology
- Humans
- Health Expenditures
- Europe
- Drug Approval
- Biosimilar Pharmaceuticals
- Biological Products
Citation
APA
Chicago
ICMJE
MLA
NLM
Lyman, G. H. (2017). Emerging Opportunities and Challenges of Biosimilars in Oncology Practice. J Oncol Pract, 13(9_suppl), 7s-9s. https://doi.org/10.1200/JOP.2017.026831
Lyman, Gary H. “Emerging Opportunities and Challenges of Biosimilars in Oncology Practice.” J Oncol Pract 13, no. 9_suppl (September 2017): 7s-9s. https://doi.org/10.1200/JOP.2017.026831.
Lyman GH. Emerging Opportunities and Challenges of Biosimilars in Oncology Practice. J Oncol Pract. 2017 Sep;13(9_suppl):7s-9s.
Lyman, Gary H. “Emerging Opportunities and Challenges of Biosimilars in Oncology Practice.” J Oncol Pract, vol. 13, no. 9_suppl, Sept. 2017, pp. 7s-9s. Pubmed, doi:10.1200/JOP.2017.026831.
Lyman GH. Emerging Opportunities and Challenges of Biosimilars in Oncology Practice. J Oncol Pract. 2017 Sep;13(9_suppl):7s-9s.
Published In
J Oncol Pract
DOI
EISSN
1935-469X
Publication Date
September 2017
Volume
13
Issue
9_suppl
Start / End Page
7s / 9s
Location
United States
Related Subject Headings
- United States
- Oncology & Carcinogenesis
- Neoplasms
- Medical Oncology
- Humans
- Health Expenditures
- Europe
- Drug Approval
- Biosimilar Pharmaceuticals
- Biological Products